Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin PK/PD in Pediatric T2DM
NCT02121483Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 48 hours, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 48 hours and 3 more. Started Jun 2014; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02121483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121483.